Beyond weight outcomes, the Phase 2 obesity trial also reported improvements in several cardiometabolic markers, including: Reductions in waist circumference Improvements in fasting glucose and insulin sensitivity Favourable changes in blood pressure and lipid profiles Phase 3 trials understood to form part of the TRIUMPH programme are now underway, evaluating retatrutide in broader populations including people with type 2 diabetes and cardiovascular disease
Tier 3 Specialist Medical/Pharmacological This works through consultation with dietitians, specialists, nurses and also requires a GP referral
13 These findings triggered interest into the extent to which these results were secondary to weight loss or were due to direct effects on HF pathobiology
In individuals with obesity or metabolic dysfunction, this hormonal signaling system often does not function optimally, leading to persistent hunger, frequent cravings, and difficulty achieving satiety even after eating adequate meals
Semaglutide is FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy)